CA2728623A1 - Combination treatment of glaucoma - Google Patents

Combination treatment of glaucoma Download PDF

Info

Publication number
CA2728623A1
CA2728623A1 CA2728623A CA2728623A CA2728623A1 CA 2728623 A1 CA2728623 A1 CA 2728623A1 CA 2728623 A CA2728623 A CA 2728623A CA 2728623 A CA2728623 A CA 2728623A CA 2728623 A1 CA2728623 A1 CA 2728623A1
Authority
CA
Canada
Prior art keywords
punctum
latanoprost
delivery system
days
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2728623A
Other languages
English (en)
French (fr)
Inventor
Zuhal Butuner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
QLT Plug Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLT Plug Delivery Inc filed Critical QLT Plug Delivery Inc
Publication of CA2728623A1 publication Critical patent/CA2728623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2728623A 2008-06-24 2009-06-24 Combination treatment of glaucoma Abandoned CA2728623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7528408P 2008-06-24 2008-06-24
US61/075,284 2008-06-24
PCT/US2009/048452 WO2010008883A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Publications (1)

Publication Number Publication Date
CA2728623A1 true CA2728623A1 (en) 2010-01-21

Family

ID=41431875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2728623A Abandoned CA2728623A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Country Status (7)

Country Link
US (1) US20090318549A1 (US20050271705A1-20051208-C00006.png)
EP (1) EP2303184A4 (US20050271705A1-20051208-C00006.png)
JP (1) JP2011525388A (US20050271705A1-20051208-C00006.png)
CN (1) CN102105118A (US20050271705A1-20051208-C00006.png)
CA (1) CA2728623A1 (US20050271705A1-20051208-C00006.png)
TW (1) TW201012469A (US20050271705A1-20051208-C00006.png)
WO (1) WO2010008883A1 (US20050271705A1-20051208-C00006.png)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470108A1 (en) 2004-07-02 2019-04-17 Mati Therapeutics Inc. Treatment medium delivery device for delivery of treatment media to the eye
RU2413480C2 (ru) 2006-03-31 2011-03-10 Клт Плаг Диливери, Инк. Способы доставки лекарственных средств, структуры и композиции для носослезной системы
MX2010002619A (es) 2007-09-07 2010-06-01 Qlt Plug Delivery Inc Deteccion de implante lagrimal.
JP2011520805A (ja) * 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達
EP4108216A1 (en) 2009-06-03 2022-12-28 Forsight Vision5, Inc. Anterior segment drug delivery
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CN103889401B (zh) 2011-08-29 2017-10-13 Qlt公司 持续释放递送活性剂以治疗青光眼和高眼压
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
PL2911623T3 (pl) 2012-10-26 2020-03-31 Forsight Vision5, Inc. System oczny do przedłużonego uwalniania leku do oka
CA2898644A1 (en) * 2013-01-24 2014-07-31 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9424722B2 (en) * 2014-05-14 2016-08-23 Unlimited Liability, LLC Smart memory material lock devices
RU2562515C1 (ru) * 2014-08-19 2015-09-10 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Интубационный набор для биканаликулярного дренирования слезоотводящих путей
US20170266391A1 (en) * 2014-09-22 2017-09-21 Kaneka Corporation Injection needle device for endoscope
US10471070B2 (en) 2014-11-25 2019-11-12 Eyal Sheetrit Methods for delivering a bio-active agent or bio-active agents to an eye of a mammal
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11291847B2 (en) * 2015-06-16 2022-04-05 The Regents Of The University Of Colorado, A Body Corporate Systems and methods for preventing, diagnosing, and/or treating one or more medical conditions via neuromodulation
CN105879126A (zh) * 2016-03-24 2016-08-24 杭州亚慧生物科技有限公司 一种超润滑血清白蛋白泪点塞及其制备方法
WO2019191700A1 (en) * 2018-03-29 2019-10-03 Mati Therapeutics Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
CN109568138B (zh) * 2019-01-10 2021-06-25 新疆国际旅行卫生保健中心 药片分割装置
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
JP3857306B2 (ja) * 1992-04-24 2006-12-13 ザ ポリマー テクノロジー グループ，インコーポレイティド 所定分子量レンジの分子を透過させるためのコポリマー及びそれらの非細孔性，半透過性膜並びにその使用
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
JP2006516618A (ja) * 2003-01-24 2006-07-06 コントロール・デリバリー・システムズ・インコーポレイテッド アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法
US20040170685A1 (en) * 2003-02-26 2004-09-02 Medivas, Llc Bioactive stents and methods for use thereof
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20070197491A1 (en) * 2005-10-14 2007-08-23 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
RU2413480C2 (ru) * 2006-03-31 2011-03-10 Клт Плаг Диливери, Инк. Способы доставки лекарственных средств, структуры и композиции для носослезной системы
CA2670944A1 (en) * 2006-12-18 2008-06-26 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
MX2010002618A (es) * 2007-09-07 2010-11-10 Qlt Plug Delivery Inc Herramientas de insercion y extraccion para implantes lagrimales.
NZ583678A (en) * 2007-09-07 2012-03-30 Quadra Logic Tech Inc Silicone matrix drug cores for sustained release of therapeutic agents
WO2009032328A1 (en) * 2007-09-07 2009-03-12 Qlt Plug Delivery, Inc Lacrimal implants and related methods
BRPI0907890A2 (pt) * 2008-02-18 2015-07-28 Qlt Plug Delivery Inc Implantes lacrimais e métodos relacionados
WO2009134371A2 (en) * 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
JP2011520805A (ja) * 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達

Also Published As

Publication number Publication date
JP2011525388A (ja) 2011-09-22
CN102105118A (zh) 2011-06-22
US20090318549A1 (en) 2009-12-24
EP2303184A1 (en) 2011-04-06
EP2303184A4 (en) 2013-06-19
TW201012469A (en) 2010-04-01
WO2010008883A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
US20200323685A1 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US20090318549A1 (en) Combination treatment of glaucoma
CA2722971C (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EP2389221B1 (en) Sustained released delivery of one or more agents
US20100274224A1 (en) Lacrimal implant body including comforting agent
US20140025022A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2872338C (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140625